Logo image of SCNI

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock Fundamental Analysis

USA - NASDAQ:SCNI - US09073Q3039 - ADR

1.5 USD
-0.13 (-7.98%)
Last: 10/9/2025, 4:04:03 PM
Fundamental Rating

1

SCNI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. SCNI has a bad profitability rating. Also its financial health evaluation is rather negative. SCNI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SCNI had positive earnings in the past year.
SCNI had a negative operating cash flow in the past year.
In the past 5 years SCNI reported 4 times negative net income.
SCNI had a negative operating cash flow in each of the past 5 years.
SCNI Yearly Net Income VS EBIT VS OCF VS FCFSCNI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

SCNI has a Return On Assets of 40.51%. This is amongst the best in the industry. SCNI outperforms 99.07% of its industry peers.
SCNI has a Return On Equity of 61.03%. This is amongst the best in the industry. SCNI outperforms 98.88% of its industry peers.
Industry RankSector Rank
ROA 40.51%
ROE 61.03%
ROIC N/A
ROA(3y)-7.65%
ROA(5y)-13.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCNI Yearly ROA, ROE, ROICSCNI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

1.3 Margins

SCNI has a better Profit Margin (728.88%) than 99.25% of its industry peers.
SCNI does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 728.88%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCNI Yearly Profit, Operating, Gross MarginsSCNI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

More info and screens

1

2. Health

2.1 Basic Checks

SCNI does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCNI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SCNI has been increased compared to 5 years ago.
The debt/assets ratio for SCNI has been reduced compared to a year ago.
SCNI Yearly Shares OutstandingSCNI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SCNI Yearly Total Debt VS Total AssetsSCNI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

SCNI has an Altman-Z score of -16.03. This is a bad value and indicates that SCNI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SCNI (-16.03) is worse than 81.72% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that SCNI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.04, SCNI perfoms like the industry average, outperforming 40.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -16.03
ROIC/WACCN/A
WACC7.15%
SCNI Yearly LT Debt VS Equity VS FCFSCNI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

SCNI has a Current Ratio of 0.71. This is a bad value and indicates that SCNI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.71, SCNI is not doing good in the industry: 90.86% of the companies in the same industry are doing better.
SCNI has a Quick Ratio of 0.71. This is a bad value and indicates that SCNI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SCNI (0.71) is worse than 90.30% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.71
SCNI Yearly Current Assets VS Current LiabilitesSCNI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%172.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNI Yearly Revenue VS EstimatesSCNI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 200K 400K 600K
SCNI Yearly EPS VS EstimatesSCNI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 -20 -40 -60

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 0.50, the valuation of SCNI can be described as very cheap.
Based on the Price/Earnings ratio, SCNI is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
SCNI is valuated cheaply when we compare the Price/Earnings ratio to 27.91, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 0.5
Fwd PE N/A
SCNI Price Earnings VS Forward Price EarningsSCNI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNI Per share dataSCNI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SCNI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCINAI IMMUNOTHERAPEUTICS LT

NASDAQ:SCNI (10/9/2025, 4:04:03 PM)

1.5

-0.13 (-7.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2024-05-15/amc
Earnings (Next)N/A N/A
Inst Owners7.84%
Inst Owner Change0%
Ins Owners2.37%
Ins Owner ChangeN/A
Market Cap4.73M
Analysts82.86
Price TargetN/A
Short Float %10.74%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.5
Fwd PE N/A
P/S 7.19
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)3.03
EY202%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0.21
BVpS2.49
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 40.51%
ROE 61.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 728.88%
GM N/A
FCFM N/A
ROA(3y)-7.65%
ROA(5y)-13.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.94%
Cap/Sales 2.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.71
Altman-Z -16.03
F-Score5
WACC7.15%
ROIC/WACCN/A
Cap/Depr(3y)91.14%
Cap/Depr(5y)108.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%172.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.48%
OCF growth 3YN/A
OCF growth 5YN/A